Table 2.

Glycemic control and lipid profile of the study subjects before and after treatment, and healthy control subjects.

	Pravastatin (n = 22)		Placebo (n = 20)		Healthy control
	Baseline	Follow-up	Baseline	Follow-up	(n = 41)
HbA1c (%)	8.3 ± 1.1	8.4 ± 1.2	8.2 ± 1.1	8.0 ± 1.1	N/A*
Total cholesterol (mmol/L)	4.4 ± 0.5	3.3 ± 0.4**	4.6 ± 0.8	4.3 ± 0.6	4.2 ± 0.7
LDL cholesterol (mmol/L)	2.4 ± 0.5	1.6 ± 0.4**	2.5 ± 0.6	2.4 ± 0.6	2.3 ± 0.6
HDL cholesterol (mmol/L)	1.6 ± 0.3	1.5 ± 0.3	1.5 ± 0.3	1.5 ± 0.3	1.5 ± 0.4
Triglycerides (mmol/L)	0.8 ± 0.3	0.6 ± 0.2	1.3 ± 1.0	0.9 ± 0.5	0.9 ± 0.4

N/A = data not available.

^*Reference range in non-diabetic subjects 4.2–6.0%

^**p < 0.001.